Oral Ferric Maltol for the Treatment of Iron-Deficiency Anemia in Patients With CKD: A Randomized Trial and Open-Label Extension

Rationale & objective: Iron-deficiency anemia is common in patients with chronic kidney disease (CKD) not requiring kidney replacement therapy (KRT). We evaluated effects of oral iron replacement therapy with ferric maltol in these patients.

Study design: Phase 3, double-blind, randomized, placebo-controlled trial (AEGIS-CKD) and open-label extension.

Setting & participants: Adults with stage 3 or 4 CKD and iron-deficiency anemia at 30 US centers.

Intervention: Oral ferric maltol at 30mg or placebo twice daily for 16 weeks (2:1 randomization) followed by ferric maltol at 30mg twice daily for up to 36 weeks (all patients).

Outcome: Change from baseline in hemoglobin (primary end point at week 16), ferritin, transferrin saturation, and serum iron; safety.

Results: 167 patients were randomized (ferric maltol, n=111; placebo, n=56). At week 16, hemoglobin had increased significantly with ferric maltol versus placebo (least-squares mean difference: 0.5±0.2 [SE] g/dL; 95% CI, 0.1-0.9; P=0.01). Ferritin, transferrin saturation, and serum iron increased with ferric maltol but declined with placebo (all P<0.05). Hemoglobin levels were sustained up to week 52 in patients continuing ferric maltol and increased in patients switching from placebo to ferric maltol. The most frequent adverse events were gastrointestinal (randomized phase: 41% vs 30% [ferric maltol vs placebo]; open-label phase: 56% vs 46%, respectively). Adverse events led to treatment withdrawal in 7 patients (6%) receiving ferric maltol and 5 patients (9%) receiving placebo during double-blind treatment, and 11 patients (9%) during the open-label extension.

Limitations: Heterogeneity in baseline ferritin levels; high proportion of female participants; single-arm open-label extension.

Conclusions: Ferric maltol was associated with statistically significant (week 16) and sustained (up to week 52) increases in hemoglobin and iron indices in patients with CKD and iron deficiency, and was well tolerated during treatment for up to 52 weeks.

Funding: Funded by Shield Therapeutics (UK) Ltd.

Trial registration: Registered at ClinicalTrials.gov with study number NCT02968368.

PMID: 34029682 DOI: 10.1053/j.ajkd.2021.03.020

Pablo E Pergola 1, Nelson P Kopyt 2

Leave a Reply

Related Posts
Exploring the Benefits and Challenges of Working with Industrial Chemical Suppliers in India

Working with industrial chemical suppliers in India can offer several benefits, but it also comes with its own set of challenges. Let’s explore both aspects: Benefits of working with industrial chemical suppliers in India Cost-effective sourcing: India is known for its competitive pricing in various industries, including chemicals. Working with Indian suppliers can often result […]

5 Benefits of Using Potassium Magnesium Citrate from a Trusted Manufacturer

When using Potassium Magnesium Citrate, sourcing it from a trusted manufacturer offers several benefits. Potassium magnesium citrate is a medication or dietary supplement that combines the minerals potassium and magnesium with citric acid. It is commonly used for various purposes due to the potential health benefits associated with these minerals. Here are some applications of […]

7 Top Benefits of Magnesium Bisglycinate

Magnesium bisglycinate is a form of magnesium that is bound to the amino acid glycine. This chelated form of magnesium offers several benefits over other forms of magnesium supplementation. Here are some of the top benefits of magnesium bisglycinate: It’s important to note that while magnesium bisglycinate offers these potential benefits, individual responses may vary. […]

Download Brochure
Contact Us